Prana Biotechnology said it got the OK from Australia's Austin Health Research Ethics Committee to move forward with a long-term Phase II trial of PBT2, its experimental drug for mild Alzheimer's disease. Researchers will use PiB-PET imaging to measure the drug's effect on amyloid deposits in patients' brains and F-FDG PET to determine effects on increasing brain activity.

Related Summaries